Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIA, International, Multicenter, Open-label, Uncontrolled Study to Evaluate The Safety And Pharmacokinetics of 4 × 375 mg/m2 Intravenous Rituximab in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01750697 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01750697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01750697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIA, International, Multicenter, Open-label, Uncontrolled Study to Evaluate The Safety And Pharmacokinetics of 4 × 375 mg/m2 Intravenous Rituximab in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
May 23, 2013
Completion date
May 10, 2018
Enrollment
25 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

granulomatosis with polyangiitis